Demographic and clinical data of 86 patients treated with anti-TNF alfa (TNF+) and 258 patients treated with DMARDs (TNF-).

Table 1: Demographic and clinical data of 86 patients treated with anti-TNF alfa (TNF+) and 258 patients treated with DMARDs (TNF-).

Characteristics		TNF+ (n. 86)	TNF- (n. 258)	p
Demographics
	F/M	68/18	200/58	0.88
	Mean age at onset, years (SD)	31.5 (12.9)	51.67 (12.9)	< 0.0001^a
	Mean RA duration at last evaluation, years (SD)	23.2 (7.2)	17.3 (8.7)	< 0.0001^a
	Mean RA duration at CV event, years (SD)	18.9 (8.2)	13.3 (7.9)	0.015^a
	Mean duration of drug exposure, years (SD)	9.69 (4.47)	13.9 (6.6)	< 0.000 1^a
	Mean duration of drug exposure until CV event, years (SD)	8.3 (3.6)	13.3 (7.9)	0.006^a
	RF (%)	57/83 (68.7%)	177/256 (69.1%)	1.0
	Anti CCP (%)	11/14 (78%)	59/91 (64.8%)	0.06
Comorbidities
	Arterial hypertension (%)	29 (33.7)	29/107 (27)	0.34
	Smoking habits (%)	22 (25.6)	30/113 (26.5)	1.0
	Dyslipidemia	7 (8)	15/104 (14.4)	0.36
	Familiar CV disease (%)	30 (34.8)	111 (43)	0.22
	Diabetes (%)	4 (4.6)	6/108 (5.6)	1.0
	Coronaropathy (%)	3 (3.5)	4 (1.5)	0.37
	Mean n. Framingham risk factors (SD)	5.6 (6.8)	7.3 (8.3)	0.18^b
RA-related drugs
	NSAIDs	63 (73.2%)	145 (56%)	0.005
	Methotrexate	71/86 (82.5%)	170 (65.8%)	0.004
	Hydroxychloroquine	18/86 (20.9%)	97 (37.6%)	0.005
	Prednisone	79/86 (91.8%)	209 (81%)	0.018
	Prednisone > 5 mg/day	32/84 (38%)	14/257 (5.4%)	< 0.0001
CV-related drugs	B blockers	14/85 (16.2%)	59/258 (22.8%)	0.2
	Ca antagonists	9/85 (10.5%)	34/258 (13.2%)	0.7
	Ace inhibitors	26/85 (30.5%)	65/258 (25.2%)	0.3
	Diuretics	16/85 (18.8%)	35/257 (13.6%)	0.3
	Anti-platelets	21/86 (24.4%)	71/258 (6.6%)	0.6
	Oral anti-coagulants	5/86 (5.8%)	14/258 (5.4%)	1.0
	Statins	7/86 (8.1%)	36/258 (13.9%)	0.2

NSAIDs: non-steroidal anti-inflammatory drugs; RF: Rheumatoid Factor; ^a = Unpaired t test; ^b = Mann Whitney test.